Journal of neuroimmunology · 2026
Borneol-Edaravone mitigates ischemic brain injury in MCAO rats.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhuang Xue-Feng, Zhang Tao, Zeng Yue-Qin, Shan Zhen-Nan, Huang Jun-Lin, Gu Juan-Hua, Pu Li-Jin, Zhou Xin-Fu, Luo Hai-Yun
Аннотация
BACKGROUND: Borneol-Edaravone, a derivative combining borneol and Edaravone, was evaluated for its neuroprotective and anti-inflammatory effects in a rat model of middle cerebral artery occlusion (MCAO), and its efficacy was compared with Edaravone alone.
METHODS: Borneol-Edaravone was administered intraperitoneally (IP) twice daily, starting at 6 h post-stroke induction and continuing for 7 days. Post-stroke outcomes, including sensorimotor function, neuroprotection, and inflammation markers were assessed.
RESULTS: As an anti-inflammatory agent(inhibited astrocyte and microglial overactivation, and reduced oxidative/nitrative stress markers (3-NT, 4-HNE), and its effectiveness in improving sensorimotor deficits and reduced cerebral infarct volume in the MCAO, Borneol-Edaravone demonstrated superior neuroprotection to Edaravone.
CONCLUSION: These findings suggest that Borneol-Edaravone exerts both neuroprotective and anti-inflammatory effects and may offer enhanced protection with an extended therapeutic window from 4.5 to 6 h against cerebral ischemia-reperfusion injury compared to Edaravone.
METHODS: Borneol-Edaravone was administered intraperitoneally (IP) twice daily, starting at 6 h post-stroke induction and continuing for 7 days. Post-stroke outcomes, including sensorimotor function, neuroprotection, and inflammation markers were assessed.
RESULTS: As an anti-inflammatory agent(inhibited astrocyte and microglial overactivation, and reduced oxidative/nitrative stress markers (3-NT, 4-HNE), and its effectiveness in improving sensorimotor deficits and reduced cerebral infarct volume in the MCAO, Borneol-Edaravone demonstrated superior neuroprotection to Edaravone.
CONCLUSION: These findings suggest that Borneol-Edaravone exerts both neuroprotective and anti-inflammatory effects and may offer enhanced protection with an extended therapeutic window from 4.5 to 6 h against cerebral ischemia-reperfusion injury compared to Edaravone.